Bicycle Therapeutics plc (BCYC) has a negative trailing P/E of -1.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 10.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -64.11%, forward earnings yield 9.73%.
Criteria proven by this page:
Overall SharesGrow Score: 54/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -15.7 | 0.00 | 26.47 | 0.00 | - |
| 2017 | -9.8 | -0.16 | -3.38 | 77.44 | - |
| 2018 | -7.3 | -0.21 | -2.28 | 22.35 | - |
| 2019 | -3.4 | -0.05 | 1.12 | 7.55 | - |
| 2020 | -6.7 | 1.70 | 3.60 | 33.08 | - |
| 2021 | -22.8 | -60.73 | 4.41 | 130.42 | - |
| 2022 | -7.8 | -0.18 | 3.24 | 60.70 | - |
| 2023 | -3.6 | -0.11 | 1.73 | 23.85 | - |
| 2024 | -4.8 | 0.11 | 1.03 | 23.10 | - |
| 2025 | -2.2 | -0.26 | 0.80 | 6.76 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.76 | $0.00 | $-13.51M | - |
| 2017 | $-1.22 | $2.06M | $-16.26M | -789.3% |
| 2018 | $-1.64 | $7.14M | $-21.85M | -306.1% |
| 2019 | $-2.77 | $13.8M | $-30.61M | -221.8% |
| 2020 | $-2.66 | $10.39M | $-51.01M | -491% |
| 2021 | $-2.67 | $11.7M | $-66.82M | -571.2% |
| 2022 | $-3.80 | $14.46M | $-112.72M | -779.3% |
| 2023 | $-5.08 | $26.98M | $-180.66M | -669.7% |
| 2024 | $-2.90 | $35.28M | $-169.03M | -479.2% |
| 2025 | $-3.16 | $72.59M | $-218.96M | -301.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.18 | $-3.07 – $-1.32 | $32.87M | $26.3M – $42.65M | 8 |
| 2027 | $-1.92 | $-2.95 – $-1.05 | $30.88M | $26.62M – $35.14M | 8 |
| 2028 | $-1.69 | $-4.49 – $2.73 | $72.75M | $70.41M – $75.09M | 8 |
| 2029 | $-0.77 | $-1.12 – $-0.52 | $126.09M | $94.34M – $170.01M | 6 |
| 2030 | $0.49 | $0.33 – $0.72 | $267.26M | $199.97M – $360.33M | 6 |
